Practical Management of Patients with Atopic Dermatitis on Dupilumab

被引：5

作者：

Papp, Kim A. ^{[1
,2
]}

Hong, Chih-ho ^{[1
,3
]}

Lansang, M. Perla ^{[4
,5
,6
]}

Turchin, Irina ^{[1
,7
]}

Adam, David N. ^{[1
,5
,8
]}

Beecker, Jennifer R. ^{[1
,9
,10
]}

Bissonnette, Robert ^{[11
]}

Gooderham, Melinda J. ^{[1
]}

Jack, Carolyn

Joseph, Marissa ^{[5
]}

Lynde, Charles W. ^{[1
,5
]}

Shear, Neil H. ^{[4
]}

机构：

[1] Prob Med Res, Waterloo, ON, Canada

[2] K Papp Clin Res, 135 Union St E, Waterloo, ON N2J IC4, Canada

[3] Dr Chihho Hong Med, Surrey, BC, Canada

[4] Sunnybrook Hlth Sci Ctr, Div Dermatol, Toronto, ON, Canada

[5] Univ Toronto, Temerty Fac Med, Div Dermatol, Toronto, ON, Canada

[6] Hosp Sick Children, Div Paediat Med, Dermatol Sect, Toronto, ON, Canada

[7] Brunswick Dermatol Ctr, Fredericton, NB, Canada

[8] CCA Med Res, Ajax, ON, Canada

[9] Ottawa Hosp, Div Dermatol, Ottawa, ON, Canada

[10] Univ Ottawa, Div Dermatol, Ottawa, ON, Canada

[11] Innovaderm Res, Montreal, PQ, Canada

来源：

DERMATOLOGY AND THERAPY | 2021年 / 11卷 / 05期

关键词：

Atopic dermatitis; Dupilumab; Practical management; HIV-1; INFECTION; EXPERT ELICITATION; PSORIASIS; PREGNANCY; DISEASES; ECZEMA; CONJUNCTIVITIS; DERMATOSES; HYPOTHESIS; RESISTANCE;

D O I：

10.1007/s13555-021-00586-w

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Introduction Dupilumab is approved to treat moderate-to-severe atopic dermatitis (AD) in several countries in patients as young as 6 years of age. Since its approval, practical issues related to the use of dupilumab for AD have arisen, with particular interest in transitioning from current therapies and managing medication overlap, considerations for special populations of patients with AD, and management of potential adverse events. Methods This article aims to review the literature addressing several practical management issues related to dupilumab use for AD and to provide a framework for clinical decision-making in these circumstances and sub-populations. Each statement was reviewed, revised and voted on by authors to provide their level of agreement and degree of uncertainty for each statement. Results An agreement level > 80% was achieved for all of the statements. Conclusion The expert panel provides statements considering the practical management of patients with AD taking dupilumab to inform clinical decision-making in specific but frequently encountered clinical situations.

引用

页码：1805 / 1828

页数：24

共 125 条

[1]

Ahn J, 2021, 11 G RAJK INT S AT D

[2] Conjunctivitis in dupilumab clinical trials [J].

Akinlade, B. ;

Guttman-Yassky, E. ;

de Bruin-Weller, M. ;

Simpson, E. L. ;

Blauvelt, A. ;

Cork, M. J. ;

Prens, E. ;

Asbell, P. ;

Akpek, E. ;

Corren, J. ;

Bachert, C. ;

Hirano, I. ;

Weyne, J. ;

Korotzer, A. ;

Chen, Z. ;

Hultsch, T. ;

Zhu, X. ;

Davis, J. D. ;

Mannent, L. ;

Hamilton, J. D. ;

Teper, A. ;

Staudinger, H. ;

Rizova, E. ;

Pirozzi, G. ;

Graham, N. M. H. ;

Shumel, B. ;

Ardeleanu, M. ;

Wollenberg, A. .

BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (03) :459-473

[3] Hyper IgE syndromes: clinical and molecular characteristics [J].

Al-Shaikhly, Taha ;

Ochs, Hans D. .

IMMUNOLOGY AND CELL BIOLOGY, 2019, 97 (04) :368-379

[4] The specific dermatoses of pregnancy revisited and reclassified:: Results of a retrospective two-center study on 505 pregnant patients [J].

Ambros-Rudolph, CM ;

Müllegger, RR ;

Vaughan-Jones, SA ;

Kerl, H ;

Black, MM .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) :395-404

[5] Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry [J].

Ariens, Lieneke F. M. ;

van der Schaft, Jorien ;

Spekhorst, Lotte S. ;

Bakker, Daphne S. ;

Romeijn, Geertruida L. E. ;

Kouwenhoven, Tessa A. ;

Kamsteeg, Marijke ;

Voorberg, Angelique N. ;

Oosting, Albert J. ;

de Ridder, Ilona ;

Sloeserwij, Annemieke ;

Haeck, Inge ;

Thijs, Judith L. ;

Schuttelaar, Marie L. A. ;

De Bruin-Weller, Marjolein S. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (04) :1000-1009

[6] Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials [J].

Bachert, Claus ;

Han, Joseph K. ;

Desrosiers, Martin ;

Hellings, Peter W. ;

Amin, Nikhil ;

Lee, Stella E. ;

Mullol, Joaquim ;

Greos, Leon S. ;

Bosso, John V. ;

Laidlaw, Tanya M. ;

Cervin, Anders U. ;

Maspero, Jorge F. ;

Hopkins, Claire ;

Olze, Heidi ;

Canonica, G. Walter ;

Paggiaro, Pierluigi ;

Cho, Seong H. ;

Fokkens, Wytske J. ;

Fujieda, Shigeharu ;

Zhang, Mei ;

Lu, Xin ;

Fan, Chunpeng ;

Draikiwicz, Steven ;

Kamat, Siddhesh A. ;

Khan, Asif ;

Pirozzi, Gianluca ;

Patel, Naimish ;

Graham, Neil M. H. ;

Ruddy, Marcella ;

Staudinger, Heribert ;

Weinreich, David ;

Stahl, Neil ;

Yancopoulos, George D. ;

Mannent, Leda P. .

LANCET, 2019, 394 (10209) :1638-1650

[7] Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions in Patients with Moderate-to-Severe Atopic Dermatitis [J].

Bakker, Daphne S. ;

van der Wal, Maria M. ;

Heeb, Lukas E. M. ;

Giovannone, Barbara ;

Asamoah, Mindy ;

Delemarre, Eveline M. ;

Drylewicz, Julia ;

Nierkens, Stefan ;

Boyman, Onur ;

de Bruin-Weller, Marjolein S. ;

Thijs, Judith L. ;

van Wijk, Femke .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (08) :1943-+

[8] Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma [J].

Bansal, Ashish ;

Simpson, Eric L. ;

Paller, Amy S. ;

Siegfried, Elaine C. ;

Blauvelt, Andrew ;

de Bruin-Weller, Marjolein ;

Corren, Jonathan ;

Sher, Lawrence ;

Guttman-Yassky, Emma ;

Chen, Zhen ;

Daizadeh, Nadia ;

Kamal, Mohamed A. ;

Shumel, Brad ;

Mina-Osorio, Paola ;

Mannent, Leda ;

Patel, Naimish ;

Graham, Neil M. H. ;

Khokhar, Faisal A. ;

Ardeleanu, Marius .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (01) :101-115

[9] Treatment interruption did not impact efficacy or long-term safety of dupilumab: A phase 3 open-label trial [J].

Beck, L. A. ;

Mette, D. ;

Zhang, Q. ;

Akinlade, B. ;

Staudinger, H. ;

Graham, N. ;

Pirozzi, G. ;

Ardeleanu, M. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) :S43-S43

[10] Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis [J].

Beck, Lisa A. ;

Thaci, Diamant ;

Deleuran, Mette ;

Blauvelt, Andrew ;

Bissonnette, Robert ;

de Bruin-Weller, Marjolein ;

Hide, Michihiro ;

Sher, Lawrence ;

Hussain, Iftikhar ;

Chen, Zhen ;

Khokhar, Faisal A. ;

Beazley, Bethany ;

Ruddy, Marcella ;

Patel, Naimish ;

Graham, Neil M. H. ;

Ardeleanu, Marius ;

Shumel, Brad .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (04) :567-577

← 1 2 3 4 5 6 7 8 9 10 →